• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Ketorolac use approved for post-cataract surgery

Article

The FDA recently approved ketorolac tromethamine ophthalmic solution 0.45% (Acuvail, Allergan) for treating pain and inflammation following cataract surgery.

Key Points

Irvine, CA-The FDA recently approved ketorolac tromethamine ophthalmic solution 0.45% (Acuvail, Allergan) for treating pain and inflammation following cataract surgery.

Ketorolac, a nonsteroidal anti-inflammatory, is formulated at pH 6.8, enabling deionized drug delivery on the corneal surface. The ketorolac formulation also contains carboxymethylcellulose to enable the drug to adhere to the ocular surface to enhance patient comfort. Additionally, it inhibits COX-1 and COX-2 enzymes, which are considered the primary sources of pain and inflammation following cataract surgery.

"With its preservative-free formulation, optimized tolerability, and twice-daily dosing convenience, we anticipate that [the ketorolac formulation] will be a valuable addition to the overall management of cataract surgery patients," said Scott Whitcup, MD, Allergan's executive vice president, research and development, and chief scientific officer.

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.